Abstract 8
Autoimmune diseases remain a leading cause of mortality among adolescents and young adults 9
worldwide. Despite their clinical impact, there are still significant knowledge gaps in our 10 understanding of immunological tolerance and its breach that characterizes the onset of autoimmune 11 diseases. Genetic associations between the histocompatibility leukocyte antigen (HLA) loci and 12 various autoimmune diseases have been well established. The HLA class I and class II molecules 13 present epitopes to T cells, and T cells play indispensable roles both in the maintenance of tolerance 14 and the pathogenesis of autoimmune diseases. Although a vast number of epitopes and reactive T cell 15 clones have been identified from animal model studies and observational studies, however, only a 16 few have been proven to be causally relevant to disease pathogenesis. Here, we propose a 17 computational framework to prioritize etiologically relevant epitopes by integrating the putatively 18 causal associations between HLA alleles and disease risk identified from population genetics; we 19 define a metric, termed "differential presentation index (DPI)," which principally reflects the relative 20 difference of epitope abundance presented onto HLA molecules whose alleles are genetically 21 predisposing to or protective against the specific disease. We systematically examined publicly 22 available epitope sequence data previously studied in the context of autoimmune diseases. Self-23 epitopes were generally more stably presented on disease-protective HLAs than non-self epitopes, 24 and hence had a negative DPI. Conversely, proteome-wide sequence alignment revealed that epitopes 25 with highly positive DPI were less similar to self. As a case study, we performed a focused analysis 26 of multiple sclerosis (MS), and identified epitopes from myelin basic protein (MBP), a well-27 established MS autoantigen, based on DPI-guided prioritization. Moreover, we found several non-28 MBP-derived self-epitopes with high DPI that are potentially involved in the pathogenesis of MS. 29
Our framework facilitates the identification of etiologically relevant epitopes across autoimmune 30 diseases with known HLA allele association, which in turn expedites the development of epitope-31 specific disease monitoring and intervention strategies. 32 1 Introduction 34 Autoimmune diseases have been shown to be more common than previously thought from 35 several epidemiological studies. The estimated total incidence and prevalence are 90 per person-years 36 and 3.2%, respectively, when summed across diseases (1, 2) . Graves' disease (GD), thyroiditis, and 37 rheumatoid arthritis (RA) are among the most common diseases (>10 per 100,000 person-years) 38 whereas other diseases such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS) are 39 relatively rare (1~10 per 100,000 person-years). Although clinical manifestations considerably vary 40 between diseases, most of the tissue/organ damage is thought to arise from the dysregulated response 41 of the adaptive immunity, both cytotoxic and humoral immunity, to self-antigens. Although 42 significant advances have been made both in the diagnosis and clinical management in the past 43 decade, in most of the diseases there remains no successful therapeutics leading to complete 44 remission and cure. Patients tend to suffer from the chronic, relapsing and refractory nature of the 45 diseases and the adverse effects of treatments, leading to poor quality of life and significant economic 46 burden. Indeed, autoimmune diseases are still among the leading causes of mortality among young 47 and middle-aged adults, particularly among females, and the mortality rate remains relatively 48 constant (3,4). 49
Very little is known about the disease-initiating processes of autoimmune diseases despite the 50 advances in our understanding of their steady-state pathophysiology. Mechanistic studies have been 51 hampered, at least in part, because of the following reasons: (i) patients with an early stage disease 52 lacking typical clinical manifestations tend not to seek a medical examination or to receive a correct 53 diagnosis, and therefore are rarely studied; (ii) it is often difficult to elucidate the mechanisms 54 essential for disease prevention and/or initiation from observational studies of patients with chronic 55 inflammation and extensive systemic involvements due to several secondary changes; (iii) etiologies 56 identified from studies utilizing genetically predisposing animal models do not necessarily reflect the 57 pathophysiology in humans. Undoubtedly, identification of epitopes relevant to the disease initiation 58 process would have significant translational implications, since recent studies have indicated the 59 possibility of antigen/epitope-specific immunosuppression via various strategies such as 60 transplantation of receptor-engineered T cells with immunomodulatory functions, and more 61
interestingly, systemic administration of peptide-MHC-based nanomedicine to reconstruct 62 physiological regulatory networks (5-9 short peptide fragment (called epitope) derived from various self-and non-self-antigens to T cells, 75 and the multifaceted roles of T cells as the master regulator of adaptive immunity and self-tolerance, 76
the contribution of T cell epitope to autoimmune diseases has been extensively studied, and 77 numerous self-and non-self-derived epitopes and cognate cross-reactive T cell clones have been 78 identified (13-15). Nevertheless, only a minority of them have been causally linked to either disease 79 initiation by pathogenic T cells or maintenance of self-tolerance by clonal deletion at thymus and/or 80 induction of regulatory T cells (Tregs) in vivo, and consequently, there remain virtually no epitope-81 specific diagnostic/therapeutic strategies clinically available to date. Therefore, an additional "filter" 82 complementary to experimental validation of T cell recognition in vitro is needed to expedite the 83 exploration of the most etiologically responsible epitopes. 84
In this context, here we propose a simple approach to prioritize epitopes with high 85 pathophysiological relevance by integrating population genetics and MHC binding prediction. We 86 hypothesized that epitopes more stably presented on the HLA molecules encoded by disease-87 predisposing alleles are more likely to be pathogenic, whereas those preferentially presented on HLA 88 molecules encoded by disease-protective alleles are more likely to contribute to tolerance. HLA loci 89 associated with specific diseases were extracted from the previous phenome-wide association study 90 (PheWAS) data (11), and MHC binding prediction was conducted bioinformatically using 91
NetMHCpan and NetMHCIIpan (16,17). We introduced a metric termed "differential presentation 92 index (DPI)" based on the predicted binding strength among predisposing and protective HLA 93
molecules. As a case study, we screened epitopes studied in the context of MS, and, as expected, 94
found that several epitopes derived from myelin basic protein (MBP), a well-characterized 95 autoantigen, ranked highly based on MS-specific DPI (18, 19) . Moreover, we found candidates of 96 MS-relevant non-MBP epitopes derived from self-antigens including SIK1, GRK2, IFNB, and EPO, 97
all of which are present and play critical roles in the central nervous system (CNS). Notably, some of 98 those newly identified epitopes had even higher MS-specific DPI than MBP epitopes. Finally, 99 examination of an experimentally verified molecular mimicry epitope dataset revealed two putatively 100 MS-predisposing mycobacterial epitopes homologous to an MBP-derived self-epitope and one 101 putatively RA-protective mycobacterial epitope homologous to mammalian 60kDa heat shock 102 protein (HSP60), a well-known Treg-inducing self-antigen (20,21 (T1D), ulcerative colitis (UC), and Wegener's granulomatosis (GPA). We classified the associated 119 HLA alleles into two categories, namely, "predisposing" and "protective," based on the odds ratios. 120
Then we screened diseases that have both predisposing and protective HLA alleles. The following 121 diseases met the criteria: AS, CD, DM, GD, JRA, SLE, MS, PMR, PBC, PSO, RA, SS, T1D, and UC 122 (Table S1 ). Next, we downloaded the linear T cell epitope data annotated with at least one cell-based 123 functional assay results from the Immune Epitope Database (IEDB) (22). Inclusion/exclusion criteria 124 in terms of assay annotations are provided in Table S2 . Epitopes were considered "immunogenic" if a 125 positive T cell response was recorded from at least one functional assay. We use this definition to 126 capture as many potentially T-cell-activating epitopes. We identified epitopes studied in the context 127 of the following autoimmune diseases: AS, CD, GD, GPA, MS, PBC, PSO, RA, SLE, SS, and T1D 128 (Table S3 ). It should be noted that these disease contexts do not necessarily guarantee the 129 pathophysiological relevance of the epitopes studied. We screened exact matches to human proteome 130 (UniProt ID: UP000005640) to identify self-derived (S) and non-self (NS) epitopes. We also aligned 131 each epitope sequence against the entire human proteome using the Smith-Waterman local alignment 132 algorithm, with a substitution matrix and gap opening/extension penalty parameters identical to those 133 utilized in the blastp-short tool (see Materials and Methods). We took three representative metrics, 134 namely, mean, maximum, and minimum, of the alignment score distribution as indicators of 135 similarity-to-self for each of the epitopes. 136
Differential presentation analysis 137
Our goal was to identify epitopes the most differentially presented among predisposing and 138 protective HLA molecules in a disease-specific context ( Figure 1 ). To this end, we first merged the 139 disease-HLA and disease-epitope association data to obtain a set of epitopes coupled with disease-140 specific predisposing/protective HLA allele information. Then, we computed the percentile rank 141 values using either NetMHCpan or NetMHCIIpan. Only four-digit HLA alleles were considered, and 142 two-digit HLA alleles were ignored in the subsequent analysis. Computation for HLA-DP/DQ alleles 143 was problematic because a DP-DQ pair must be provided for the binding prediction, despite the 144 single allelic format of disease association in the PheWAS source data. We ended up computing 145 every single possible combination of DP-DQ alleles that contain at least one disease-associated allele 146
and summarizing the predicted values by taking their medians. We then summarized the sign-147
inverted log-transformed percentile rank values among protective and predisposing HLAs by taking 148 their mean, maximum and minimum. Note that, after this conversion, the larger value reflects more 149 stable binding. We defined "differential presentation index (DPI)" as the difference between the 150 maximum values among predisposing and protective HLAs. We utilized the maximum value among 151
HLAs tested because any epitope does not necessarily bind strongly to all disease-associated HLAs; 152 strong binding to at least one disease-associated HLA is adequate as the initial inclusion criteria. DPI 153 is an indicator unique to each epitope defined in a disease-specific context. A positive DPI means that 154 the epitope is predicted to be bound more strongly to at least one of the predisposing HLAs than any 155 of the protective HLAs. We then categorized epitopes with DPI > 0.5 and DPI < -0.5 as 156
"predisposing" and "protective," respectively. Note that these epitope-level categories are putative. 157 We excluded epitopes if the minimum percentile rank among all disease-associated HLAs was higher 158 than the recommended threshold (2% and 10% for HLA-I and HLA-II, respectively). Figure 2 shows 159 the distributions of the lowest percentiles among predisposing and protective HLAs. Both the number 160 of available epitope data and their distribution considerably varied between diseases. There was a 161 relatively large number of epitopes associated with MS, RA, and T1D ( Figure 2B ). Full epitope data 162 is summarized in Table S4 . 163
Next, we explored the common characteristics among the differentially presented epitopes. 164
Interestingly, predisposing epitopes were significantly more likely to be derived from non-self 165 antigens than protective epitopes (P=3.2×10 -6 and 4.7×10 -7 in HLA-I and HLA-II, respectively, by 166 chi-square test) ( Figure 3A ). Meanwhile, we noted that 31/55 (56%) of HLA-I predisposing epitopes 167
were classified as non-immunogenic, meaning that there was not even a single positive T cell assay 168 result ( Figure 3B ). The difference in terms of immunogenicity between predisposing and protective 169 epitopes was also statistically significant in HLA-I but not in HLA-II epitopes (P=2.5×10 -7 and 0.35, 170 respectively, by chi-square test). To quantitatively assess similarity-to-self, we chose the highest 171 sequence alignment scores, representing the best-match sequence-level homology against the human 172 proteome. As expected, epitopes exactly matched to human proteome had apparently higher scores 173 ( Figure 3C ). Notably, the predisposing epitopes were less similar to self (P=1.6×10 -6 and 1.1×10 -6 in 174
HLA-I and HLA-II, respectively, by Wilcoxon rank sum test) ( Figure 3D ). Consistently, the overall 175 correlation between DPI and similarity-to-self was evident, although we noted considerable variation 176 between diseases ( Figure S1 ). Of note, MS-associated predisposing epitopes with high DPI were 177 more non-self, an observation not contradictory to the molecular mimicry hypothesis (13,23,24). In 178 contrast, no correlation was observed among T1D-associated epitopes, possibly indicating an 179 indispensable role of aberrantly formed self-epitopes (25, 26) . It is difficult to interpret epitopes 180 associated with other diseases due to the paucity of data. Type 2 ANOVA revealed that neither 181
peptide category or T cell reactivity significantly contributed to the similarity-to-self variation after 182 stratified by peptide origin (S vs. NS) in HLA-I, whereas mutual interaction between peptide 183 category and origin existed (P=2.7×10 -9 ) in HLA-II ( Figures 3E and F) . It was unexpected to us that 184 T cell recognition was not associated with the similarity-to-self score. We did not either observe any 185 difference among immunogenic epitopes and non-immunogenic MHC binders in the datasets we 186
have previously compiled (N=21,162 and 31,693 for HLA-I and HLA-II epitopes, respectively) 187
( Figure S2 ) (27) (manuscript under review in Frontiers in Immunology). 188
In summary, (i) predisposing epitopes are generally less similar to self, primarily because 189
peptides derived from non-human antigens tend to be more stably presented on predisposing HLAs; 190
(ii) predisposing HLA-I but not HLA-II epitopes are less likely to be recognized by T cells; and (iii) 191
propensity of T cell recognition is orthogonal to peptide similarity-to-self. 192
Case study: multiple sclerosis 193
We next asked whether the proposed DPI-based framework was able to effectively prioritize 194 known antigens/epitopes. To examine this, we decided to do a focused analysis of MS-associated 195 epitopes because of the abundance of available epitope data. DPIs were calculated based on the 196 binding prediction to four and six HLA-I and HLA-II alleles associated with MS, among which two 197 and three were MS-predisposing, respectively. More than 75% of both HLA-I and HLA-II MS-198 predisposing epitopes did not match to the human proteome (P=2.3×10 -4 and 1.1×10 -5 in HLA-I and 199
HLA-II, respectively, by Fisher's exact test) ( Figure 4A ). Meanwhile, there was a striking 200 dissociation in terms of T cell recognition between HLA-I and HLA-II MS-predisposing epitopes 201 (P=6.0×10 -8 and 1.0×10 -5 in HLA-I and HLA-II, respectively, by Fisher's exact test) ( Figure 4B ). 202
Interestingly, most of the non-self, non-immunogenic, yet predisposing HLA-I epitopes were derived 203 from human endogenous retrovirus W (HERV-W). Predisposing epitopes had lower similarity-to-self 204 compared to protective epitopes in HLA-I but not in HLA-II data (P=4×10 -5 and 0.07 in HLA-I and 205
HLA-II, respectively, by Wilcoxon rank sum test) ( Figure 4C ). We speculated that this is owing to a 206 set of predisposing HLA-II epitopes highly homologous to MBP-derived epitopes. As expected, a 207 subset of non-MBP-derived predisposing HLA-II epitopes shared high sequence homology to MBP 208 (P=0.3 and 1×10 -4 in HLA-I and HLA-II, respectively, by Wilcoxon rank sum test) ( Figure 4D ). 209
Finally, we found that DPI-guided prioritization enriched MBP-derived epitopes among self-epitopes 210 (P=0.01 and 1×10 -4 in HLA-I and HLA-II, respectively, by Wilcoxon rank sum test) ( Figure 4E ). 211
Encouraged by these observations, we next sought to screen epitopes potentially relevant to MS 212 etiology. We applied our DPI calculation framework to all self-epitopes identified from the 213 previously compiled epitope datasets (Table S5 ) (27). The top five putatively MS-predisposing 214 epitopes for both HLA-I and HLA-II are shown in Table 1 . Interestingly, the top-ranked HLA-I 215 epitope RPRPVSPSSL is derived from salt-inducible kinase1 (SIK1). The fourth HLA-I epitope 216
KPRSPVVEL is derived from G-protein coupled receptor kinases 2 (GRK2). Notably, the top-ranked 217 HLA-I epitopes had even higher MS-specific DPI than MBP-derived epitopes. Likewise, among 218
HLA-II epitopes, two interferon beta (IFN-)-and two erythropoietin (EPO)-derived epitopes were 219
identified (Table 1) . MBP-derived HLA-II epitopes were excluded from Table 1 but can be found in  220  Table S5 . IFN- has traditionally been used as an immunomodulatory drug for MS, and is thought to 221 act as a suppressor for T helper type 1 (Th1) cells and T helper 17 (Th17) cells (28-30). EPO, 222
although initially identified as an essential factor for hematopoiesis secreted from kidney, has been 223 implicated as a potent neuroprotective agent (31). In addition to MS-predisposing epitopes, we also 224 explored the putatively MS-protective epitopes. The top five putatively MS-protective HLA-II 225 epitopes are shown in Table 2 . Of note, two glutamic acid decarboxylase (GAD) epitopes were 226
identified. Note that we labeled epitopes as "disease-protective" based on genetic association, and 227
hence it does not necessarily guarantee their role in the maintenance of self-tolerance (e.g., induction 228
of Tregs). Nevertheless, it is possible that at least some epitopes with considerably low DPIs act as 229
Treg-inducing epitopes. We will discuss this point in the next chapter. 230
Case study: molecular mimicry 231
Molecular mimicry has been proposed as one of the potential mechanisms underlying the 232 breach of self-tolerance and autoimmunity (23,32-34). However, the pathophysiological significance 233 of the T cell clones recognizing both self-and pathogen-derived epitopes in vivo remains 234 undetermined or inconclusive in most cases. Moreover, recognition of a specific epitope by effector 235
T cells in vitro does not preclude the possibility of recognition of the same epitope by Tregs in vivo, 236
which may overall result in the protection against disease. 237
Self-and pathogen-derived epitopes associated with diseases in the same direction are likely to 238
share biological roles as well as sequence-level homology. Thus, we searched pairs of human-239 pathogen epitopes that have the differential presentation category in common. We utilized the 240 miPepBase, a database of experimentally verified self-epitopes and mimicking pathogen-derived 241 epitopes (35) . Surprisingly, among the forty-three epitope pairs identified, only four had the same 242 differential presentation category in common (Table 3) . Of note, there were two mycobacterium 243 epitopes associated with MS. The role of mycobacteria in the pathogenesis of MS remains 244 controversial (36), and therefore the two mycobacterial epitopes and the corresponding self-epitope 245 appear to be worth being further investigated. Meanwhile, there was one epitope pair associated with 246 putative RA protection. Interestingly, both epitopes are derived from heat shock protein (HSP). It is 247 known that cell stress-induced up-regulation of HSPs and the resultant presentation of HSP epitopes 248
induce Tregs (37). Indeed, T cell clones cross-reactive to epitopes derived from mammalian HSP60 249 and M. bovis HSP65 have been shown to protect against experimental arthritis, strongly suggesting 250 the involvement of Tregs (20,38). The comprehensive set of epitope pairs tested are summarized in 251 Table S6 . 252
Discussion

253
We systematically mined several T cell epitope candidates likely to be etiologically relevant 254 across autoimmune diseases by differential presentation onto genetically inferred disease-255 predisposing and -protective HLA molecules. T cells have been thought to play multifaceted roles 256 both in the maintenance of physiological self-tolerance and in autoimmune diseases. To date, T cells 257 epitopes presented on HLA molecules whose alleles are genetically associated with disease 258 predisposition have been extensively studied. However, to our knowledge, there are yet few studies 259 systematically comparing epitope presentation on both predisposing and protective HLAs. Probably, 260 one reason is that testing multiple HLA alleles experimentally is labor-intensive and cost-prohibitive. 261
For example, there are 38 HLA alleles significantly associated with T1D based on the PheWAS data 262
we utilized in this study. Instead of experimental testing, we conducted a comparative analysis 263 through a bioinformatic approach, which can be adequate for a screening purpose. The DPI-based 264 classification system of putatively predisposing and protective epitopes proposed in this study is a 265 novel approach complementary to the current standard approach, i.e., detection of cognate T cell 266 clones. We used percentile rank for differential presentation analysis because this metric is not 267 affected by inherent bias of specific HLA molecules towards higher or lower mean predicted 268 affinities and thus allows a direct comparison between different HLA molecules (16). We used the 269 lowest percentile rank values among predisposing and protective HLA molecules for determining the 270 degree of differential presentation. This definition is conceptually equivalent to the comparison 271 between two hypothetical populations having either all disease-specific predisposing or protective 272 HLA alleles (instead of six HLA alleles per individual in the real-world). We did not consider the 273 odds ratio of different HLA alleles for a specific disease. For example, the odds ratios among T1D-274
and MS-predisposing HLA-II alleles ranges from 4.420 to 1.713 and 2.672 to 3.475, respectively. 275
Whether odds-ratio-weighted metric contributes to better prioritization of etiologically relevant 276 epitope may be a topic of further investigation. 277
One of the advantages of computational screening is its unbiasedness; experimental approach 278 often focuses on either known epitopes or epitopes from known antigens, although this type of 279 investigation is likely to overlook epitopes of bona fide etiological significance derived from 280 unknown antigens. We tackled this issue by performing an unbiased screen of epitope candidates 281 differentially presented onto MS-predisposing and -protective HLA molecules as a case study. As 282 expected, our analysis revealed several MBP-derived epitopes. The current consensus is that MS is a 283
T cell-mediated autoimmunity against myelinated self-antigens including MBP, and the etiological 284 significance of MBP in MS has been well documented (18,39). Therefore, this enrichment of MBP-285 derived epitopes can be viewed as an internal positive control for the analysis. Furthermore, we 286
identified several self-antigens, including SIK1, GRK2, IFNB, and EPO, as a potential source of 287 etiologically relevant epitopes. First, SIK1 mutations have been documented as a cause of severe 288 developmental epilepsy (40,41). Second, a previous study of experimental autoimmune 289 encephalomyelitis, a mouse model for MS, has shown that GRK2 +/mice expressing 50% of the 290 GRK2 protein did not suffer from relapses unlike the wild-type animals, and the absence of relapse 291 was associated with a marked reduction of infiltrating inflammatory cells in the CNS (42). 292
Modulation of the Toll-like receptor signaling via GRK2 in microglia was also reported (43). Third, 293 IFN- is a naturally occurring cytokine mediating a wide range of anti-inflammatory responses in the 294 CNS, and has been used as a therapeutic agent for MS (28,30). The formation of neutralizing 295 autoantibody against therapeutically administered IFN- strongly suggests a pre-existing humoral 296 immune response against this self-antigen (44). Fourth, EPO is an endogenous neuroprotective 297 protein, and its efficacy has been shown in a pre-clinical model and a small clinical trial, although the 298 subsequent study failed to show its superiority (31, 45, 46) . Besides the putatively MS-predisposing 299 self-antigens, we also identified putatively MS-protective candidate self-antigens including GAD. 300
GAD catalyzes the synthesis of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, 301 from glutamate, and hence has an indispensable role in the physiology of GABAergic neurons (47). 302
Notably, anti-GAD autoantibodies are present not only in type 1 and 2 diabetes mellitus, but also in 303 various neurological diseases including stiff-person syndrome, Miller Fisher syndrome, limbic 304 encephalopathy, cerebellar ataxia, eye movement disorders, and epilepsy, but usually not in MS (48). 305
Collectively, aberrant T cell-mediated autoimmunity against these endogenous self-antigens may 306 disrupt the physiological integrity of the CNS microenvironment and thereby contribute to the 307 pathogenesis of MS. Moreover, these findings underscore the potential utility of an unbiased 308 computational screen in search of etiologically relevant epitopes contributing to the onset and/or 309 aggravation of various autoimmune diseases. 310
The general principles of Treg-inducing epitopes have remained largely undefined. Treg-311 inducing epitopes identified from IgG are well-known examples (49, 50) , which has been thought to 312 at least partially explain the beneficial immunomodulatory effects of high-dose intravenous 313 immunoglobulin (IVIg) therapy for some autoimmune and autoinflammatory diseases (51). However, 314
the immunomodulatory effect of IgG-derived epitopes is apparently not disease-specific. 315
Identification of disease-specific, etiologically relevant novel Treg-inducing epitopes would provide 316 valuable insights into the pathophysiological mechanisms of various autoimmune diseases, and may 317 also pave the way toward epitope-specific immunomodulatory therapeutics (5, 9, 52) . Notably, we 318
found that the majority of the HLA-I predisposing epitopes, although apparently derived from non-319 self proteome, do not have any positive T cell assay annotation in IEDB. This may be explained as a 320 reflection of tolerance mechanisms leading to clonal anergy or deletion, although overinterpretation 321 should be avoided due to the retrospective nature of this study. In a case study of MS-associated 322 epitopes, we noted that the vast majority of HLA-I predisposing epitopes were derived from HERV-323 W. HERV-W has also been called MS-associated retrovirus (MSRV) and extensively studied as a 324 potential etiology of MS (53). A recent meta-analysis showed a strong association between detectable 325
HERV-W mRNA and MS (54). Since HERV had been integrated into the human genome in 70 to 30 326 million years ago, representing almost 8% of the entire human genome, it is not surprising that our 327 adaptive immunity tolerates HERV proteins. Indeed, recent studies highlighted the indispensable role 328 of CD8 + Tregs, as well as conventional CD4 + Foxp3 + Tregs, both in the maintenance of self-tolerance 329 and suppression of antiviral immunity (55,56). Likewise, our analysis of molecular mimicry epitopes 330 revealed human and mycobacteria HSPs as a source of RA-protective HLA-II epitopes, which is 331 consistent with previous observations that HSP-derived epitopes induce CD4 + Tregs and provide 332 protection against adjuvant-induced arthritis in mice (20,38). Therefore, a set of HLA-I non-self 333 epitopes with high DPI but without evidence of T cell recognition, and a set of HLA-II self-epitopes 334 with low DPI, may be considered a good starting point in the exploration of Treg-inducing epitopes 335 in a disease-specific context. Further research is warranted to test the generalizability of this concept. 336 Molecular mimicry has long been suspected as a general principle of the etiology of various 337 autoimmune diseases. A critical obstacle in the research of molecular mimicry is, in our opinion, that 338 whether any pair of self-and pathogen-derived epitopes have etiological relevance in the same 339 direction, i.e., predisposition to or protection against disease, cannot be argued either based on 340 sequence homology or recognition by the same T cell clones alone. Our framework thus provides one 341 additional layer of criteria for molecular mimicry. It is notable that only four among 43 pairs of self-342 and pathogen-derived epitopes met the new criteria, which indeed implies that sequence-homologous 343 human and pathogen-derived epitopes could have a distinct impact in terms of disease initiation. This 344 larger-than-expected dissociation between self-epitopes and homologous pathogen-derived epitopes 345 needs to be tested using experimental animal models. In particular, it may be interesting to 346 investigate the putatively disease-predisposing pathogen-derived epitopes homologous to putatively 347 disease-protective self-epitopes. This is because the adaptive immunity in individuals with disease-348 predisposing HLA alleles may be naïve to the self-epitopes that are likely to be abundantly presented 349 on disease-protective HLA molecules (i.e., potentially tolerance-inducing), and therefore may not be 350 able to tolerate the homologous pathogen-derived epitopes suddenly beginning to be presented upon 351 infection/reactivation of the pathogen(s). Therefore, we would like to propose that etiological roles of 352
pathogen-derived mimicking epitopes should be investigated in a fashion that integrates genetic 353 association, HLA binding, and T cell recognition both in vitro and in vivo.
The caveats of our concept of differential presentation-based epitope prioritization are as 355 follows. First, the association between disease status and HLA loci does not guarantee an etiological 356 involvement of the encoded HLA molecules, due to the possibility of linkage disequilibrium. Second, 357 affinity to HLA is not the sole parameter explaining pathogenicity (12). For example, the expression 358 level and/or stability of HLA molecules can matter; for example, the low stability of HLA-DQ6 is 359 thought to confer protection against various autoimmune diseases. Moreover, entirely different 360 immunological consequences (i.e., induction of cytopathic vs. regulatory T cells) resulting from 361 alternative TCR docking due to different peptide register have been reported (15). Third, sequence-362 based affinity prediction may not always reflect the bona fide affinity in vivo. A good example is 363 post-translationally modified epitopes such as citrullinated epitopes bound to RA-predisposing HLA-364 DR4 (57 Associations between autoimmune diseases and HLA alleles were extracted from a previous 376
PheWAS study (11) . This study involved two populations of European ancestry individuals 377 (N=28,839 Wegener's granulomatosis (GPA). Only HLA alleles with P values of less than 0.01 were included in 386 the analysis. HLA alleles with odds ratios (ORs) of higher and lower than 1 were considered disease-387 predisposing and disease-protective, respectively. Only autoimmune diseases having both 388 predisposing and protective alleles were included in the subsequent analysis. Disease-HLA 389 associations are summarized in Table S1 . 390 391
Epitope sequence datasets 392
HLA-I-restricted epitope sequences of 8-aa to 14-aa lengths and HLA-II-restricted epitope sequences 393 of 9-aa to 32-aa lengths previously studied in the context of autoimmunity with annotations of 394 functional T cell assay results were collected from Immune Epitope Database (IEDB, as of 395
November 19 th , 2018) (22). Inclusion/exclusion criteria in terms of T cell assay annotation were 396 provided in Table S2 . Epitopes studied in non-human hosts were excluded. Post-translational 397 modifications of epitope sequences were not considered. Epitopes studied in the context of the 398 following autoimmune diseases were identified: AS, CD, GD, GPA, MS, PBC, PSO, RA, SLE, SS, 399 and T1D. Disease-epitope associations and accompanying annotations are summarized in Table S3 . 400 401 HLA binding prediction 402
All four-digit HLA alleles significantly associated with a specific autoimmune disease X were 403 used for HLA binding prediction of an epitope Y that has been studied in the context of X. 404
NetMHCpan 4.0 and NetMHCIIpan 3.2 were utilized for HLA binding prediction with default 405 parameter sets (16, 17) . For HLA-DP and DQ alleles, the prediction was conducted for all 406 combinations between the disease-associated target allele and all available counterparts. For example, 407
HLA-DQA1*0102 is associated with predisposition to MS. In this case, binding was predicted 408 against all possible combinations of HLA-DQA1*0102 and HLA-DQB alleles. Then, medians of 409 both predicted affinities and percentile rank values were taken as representative values for the HLA-410 DQA1*0102 allele. 411 412
Differential presentation analysis 413
Predicted percentile rank was chosen as a metric for the strength of epitope binding because 414 this metric is not affected by inherent bias of specific HLA molecules towards higher or lower mean 415 predicted affinities and thus allows a direct comparison between different HLA molecules (16). The 416
highest values of sign-inverted log10-transformed percentile ranks, corresponding to the lowest 417 percentile ranks, among predisposing and protective HLA molecules were adopted for differential 418 presentation analysis. Differential presentation index (DPI) was defined as the transformed value of 419 predisposing alleles subtracted by that of protective alleles. DPI is disease-dependent because the sets 420 of predisposing and protective alleles vary between diseases. Epitopes were then categorized in a 421 binary fashion; epitopes with DPI of higher than 0.5 and lower than -0.5 were considered putatively 422 disease-predisposing and putatively disease-protective. Note that epitopes predicted not to bind to 423 any of the disease-associated alleles, with the thresholds being 2% and 10% for HLA-I and HLA-II 424 binding prediction, respectively, were excluded from this binary categorization. 425
Categorical associations were tested between putative disease association, self/non-self origin, 426 and T cell recognition. Origin was determined by aligning the epitope sequence to the human 427 proteome (UniProt ID: UP000005640). Epitopes with at least one exact match against the human 428 proteome were defined as self-epitopes. T cell recognition (i.e., immunogenicity) was determined 429 from the IEDB annotation. The existence of at least one qualitatively positive functional T cell assay 430 result was considered evidence of immunogenicity. Note that non-functional assays such as binding 431
to peptide-MHC tetramer were not considered for determining immunogenicity. Inclusion/exclusion 432 criteria in terms of T cell assay annotation were provided in Table S2 . 433
Similarity-to-self was measured by aligning the peptide sequence against the entire human 434 proteome (UniProt ID: UP000005640). Pairwise sequence alignment was performed using the 435 pairwiseAlignment function implemented in the Biostrings package (59 Several genetic associations between HLA alleles and various autoimmune diseases have been 645 identified. Given the biological function of HLA molecules, we hypothesized that HLA molecules 646 whose alleles are genetically associated with disease predisposition presumably present either 647 pathogenic epitopes more or protective epitopes less, and likewise, HLA molecules whose alleles are 648 genetically associated with disease protection presumably present either pathogenic epitopes less or 649 protective epitopes more. Note that this scheme is oversimplified from the following viewpoints; 650 first, the genetic association with HLA loci could result from other etiologically responsible loci in 651 linkage disequilibrium; second, the different contribution to disease pathogenesis between HLA 652 alleles could be explained in multiple ways other than differential epitope presentation (12); lastly, 653
although in this study we use the percentile rank values predicted by either NetMHCpan or 654
NetMHCIIpan as a surrogate of the stability of epitope presentation, neither affinity or affinity-based 655 percentile rank is the only parameter representing the HLA-epitope thermodynamic interaction. 656 Tables   698   Table 1 . Putatively MS-predisposing non-MBP-derived self-epitopes. DPI was calculated based 699 on the predicted binding to MS-associated HLAs. Top five epitopes were shown. A complete list of 700 epitopes examined can be found in Table S5 Table 3 . Human-and pathogen-derived HLA-II epitope pairs having the same differential presentation category in common. A 707 complete list of epitopes examined can be found in Table S6 . 708 Figure S1 . Correlations between DPI and similarity-to-self. (A) DPI-selfness two-dimensional plots of autoimmunity-associated HLA-I and HLA-II epitopes. Autoimmunity-associated epitopes were analyzed, and disease-specific DPI scores were calculated. The highest alignment score against the human proteome (UniProt ID: UP000005640) was also computed for each of the epitopes. (B and C) Two-dimensional plots of (B) HLA-I and (C) HLA-II epitopes facetted by the associated diseases. R indicates Pearson's correlational coefficient. For disease abbreviations, see Figure 2 . Figure S2 . Minimal differences of similarity-to-self among immunogenic and non-immunogenic epitopes. Epitopes studied in various contexts were compiled previously. Epitopes of self (S) and non-self (NS) origins were identified based on the presence or absence of at least one exact sequence match in the human proteome. Immunogenicity was determined based on the presence or absence of at least one positive T cell assay annotation. Table S1 . A summary of disease-HLA allele associations. Table S2 . Inclusion/exclusion criteria for T cell assay annotations. Table S3 . A summary of epitopes previously studied in the context of autoimmune diseases. Table S4 . The results of differential presentation analysis in autoimmunity-associated epitopes. Table S5 . The results of MS-specific differential presentation analysis in self-epitopes previously studied in various contexts. Table S6 . The results of differential presentation analysis in self-epitopes and corresponding pathogen-derived epitopes with evidence of molecular mimicry.
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